{"ctNumber":"2023-503617-30-02","ctStatus":"Authorised","startDateEU":"2025-02-26","decisionDate":"2024-05-28T07:46:20.747","publishDate":"2026-08-14T03:39:47.49156118","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":140578,"rowSubjectCount":0,"products":[{"id":585913,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9569176","productPharmForm":"INFUSJONSVÆSKE, OPPLØSNING","euMpNumber":"PRD8079974","marketingAuthNumber":"12-9111","prodAuthStatus":2,"prodName":"Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"APOMORPHINE HYDROCHLORIDE HEMIHYDRATE","euSubstNumber":"SUB12924MIG","authorisationCountryCode":"NO","mrpNumber":"SE/H/1272/001","nameOrg":"EVOLAN PHARMA AB","productSubstances":[{"productPk":"9569176","substancePk":"258501","nameOrg":"EVOLAN PHARMA AB","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"APOMORPHINE HYDROCHLORIDE HEMIHYDRATE","substanceEvCode":"SUB12924MIG"}],"atcCode":"N04BC07","atcName":"APOMORPHINE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD8079974","devices":[],"characteristics":["2"],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":true,"productName":"Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning","jsonActiveSubstanceNames":"apomorphine hydrochloride hemihydrate","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":585912,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10320433","productPharmForm":"INFUSJONSVÆSKE, OPPLØSNING","euMpNumber":"PRD2128245","marketingAuthNumber":"5846","prodAuthStatus":2,"prodName":"Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske, oppløsning","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"SODIUM CHLORIDE","euSubstNumber":"SUB12581MIG","authorisationCountryCode":"NO","nameOrg":"FRESENIUS KABI NORGE AS","productSubstances":[{"productPk":"10320433","substancePk":"271557","nameOrg":"FRESENIUS KABI NORGE AS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"SODIUM CHLORIDE","substanceEvCode":"SUB12581MIG","synonyms":["SODIUM CHLORID","SODIUM CHLORIDE (FOR PH ADJUSTMENT)"]}],"atcCode":"B05BB01","atcName":"ELECTROLYTES","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"3","orphanDrugEdit":false,"doseUom":"mg/g milligram(s)/gram","maxDailyDoseAmount":"10","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD2128245","devices":[],"characteristics":[],"routes":["INTRAVENOUS"],"allSubstancesChemicals":true,"productName":"Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske, oppløsning","jsonActiveSubstanceNames":"sodium chloride","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":585914,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10405999","productPharmForm":"CAPSULES","euMpNumber":"PRD10405999","prodAuthStatus":1,"prodName":"PEX010 Psilocybin Capsules ( 25mg psilocybin)","pharmForm":"CAPSULES","activeSubstanceName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","euSubstNumber":"SUB267722","nameOrg":"RIGSHOSPITALET","productSubstances":[{"productPk":"10405999","substancePk":"267731","nameOrg":"RIGSHOSPITALET","substanceOrigin":"Specified Substance Group 1","actSubstOrigin":"Specified Substance Group 1","actSubstName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","substanceEvCode":"SUB267722"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"25","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"25","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10405999","miaNumber":"244/0575/18","devices":[],"characteristics":["2","9"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"PEX010 Psilocybin Capsules ( 25mg psilocybin)","jsonActiveSubstanceNames":"dry extract from psilocybe cubensis (15-25:1), extraction solvent: methanol","pharmaceuticalFormDisplay":"CAPSULES"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)","fullTitleTranslations":[],"publicTitle":"Boosting recovery through excitation of arousal and awareness in comatose patients: Dose finding study (BREA2KTHROUGH DOSEFINDER)","publicTitleTranslations":[],"secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"3","trialCategory":"2","justificationForTrialCategory":"This is an embedded dose-finding phase 1 study (n=12 patients, i.e., 4 patients with 1mg, 4 patients with 10mg, and 4 patients with 25mg; BREA2KTHROUGH DOSEFINDER) for safety, followed by a regional collaborative, randomized trial with 1:1:1 allocation of n=384 comatose patients in the ICU (phase 2, BREA2KTRHOUGH TRIAL).","trialCategoryId":129946},"medicalCondition":{"partIMedicalConditions":[{"id":147255,"medicalCondition":"Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injury","medicalConditionTranslations":[],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"4","trialScopeId":427463}],"mainObjective":"To do a dose escalation study to establish the safety of utilizing apomorphine and psilocybin in unresponsive ICU patients with acute brain injury. This is a prospective, open-label, phase 1b, dose escalation study (n=80 patients, i.e., 26 patients with 1 mg psilocybin, 27 patients with 10 mg, and 27 patients with 25 mg psilocybin; all 80 patients receive apomorphine 1-2h after psilocybin administration). The study is authorized and registered as EU-CT 2023-503617-30-02 and is currently recruiting patients as of June 2026. NB: The earlier version EU-CT 2023-503617-30-01 referred to under “Justification for trial category” was subsequently modified after request from the Ethics committee.","mainObjectiveTranslations":[],"secondaryObjectives":[{"id":502757,"number":1,"secondaryObjective":"To investigate for somatic and neuropsychiatric adverse events","secondaryObjectiveTranslations":[]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":956878,"number":1,"principalInclusionCriteria":"Age ≥ 18 years","principalInclusionCriteriaTranslations":[]},{"id":956879,"number":2,"principalInclusionCriteria":"Fluent in Danish or English language","principalInclusionCriteriaTranslations":[]},{"id":956880,"number":3,"principalInclusionCriteria":"Admission to ICU for severe acute brain injury after trauma, a cerebrovascular accident or anoxic-ischemic/metabolic injury (typically after cardiac arrest) causing coma or another acute DoC (i.e., UWS/VS, MCS), diagnosed by trained investigators","principalInclusionCriteriaTranslations":[]},{"id":956881,"number":4,"principalInclusionCriteria":"Unconsciousness is expected by the attending physicians to last for ≥3 days","principalInclusionCriteriaTranslations":[]},{"id":956882,"number":5,"principalInclusionCriteria":"Written informed consent for trial participation from both the trial guardian and next-of-kin","principalInclusionCriteriaTranslations":[]}],"principalExclusionCriteria":[{"id":1634145,"number":1,"principalExclusionCriteria":"Ongoing infusion of sedatives/continuous pharmacological sedation (We aim for unsedated patients during neurological examinations, pupillometry and NIRS-EEG, but if patients cannot fully be weaned from sedation, dosages are reduced to the lowest possible level.)","principalExclusionCriteriaTranslations":[]},{"id":1634146,"number":10,"principalExclusionCriteria":"Lack of Danish or English language proficiency","principalExclusionCriteriaTranslations":[]},{"id":1634147,"number":11,"principalExclusionCriteria":"Lack of next-of-kin consent","principalExclusionCriteriaTranslations":[]},{"id":1634148,"number":12,"principalExclusionCriteria":"Residency outside of Denmark","principalExclusionCriteriaTranslations":[]},{"id":1634149,"number":2,"principalExclusionCriteria":"Expected survival <7 days","principalExclusionCriteriaTranslations":[]},{"id":1634150,"number":3,"principalExclusionCriteria":"Known severe psychotic disorder (e.g., schizophrenia, psychosis after drug abuse, psychotic major depression, current major depression, bipolar disease, but previous history of major depression without psychosis allowed) or a history of a first-degree relative with such a disorder","principalExclusionCriteriaTranslations":[]},{"id":1634151,"number":4,"principalExclusionCriteria":"Deafness, blindness, or bilateral eye surgery before the onset of brain injury","principalExclusionCriteriaTranslations":[]},{"id":1634152,"number":5,"principalExclusionCriteria":"Ongoing use of dopamine agonists or antagonists within 6 half-lives of the drug","principalExclusionCriteriaTranslations":[]},{"id":1634153,"number":6,"principalExclusionCriteria":"Ongoing or previous use of psychoactive or psychotropic substances (including, but not limited to monoamine oxidase inhibitors or medications that are known as uridine diphosphate glucuronosyltransferase enzyme modulators; and ongoing treatments with selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitors medications because of the potential to increase the risk of serotonin syndrome) 2 weeks prior examination or within 6 half-lives of the drug","principalExclusionCriteriaTranslations":[]},{"id":1634154,"number":7,"principalExclusionCriteria":"Cardiac valvular disease and pulmonal hypertension (for a theoretical concern that serotonergic agents might aggravate these conditions)","principalExclusionCriteriaTranslations":[]},{"id":1634155,"number":8,"principalExclusionCriteria":"Recovery of the ability to follow commands consistently prior to enrolment","principalExclusionCriteriaTranslations":[]},{"id":1634156,"number":9,"principalExclusionCriteria":"Females of childbearing potential, unless negative HCG test is present","principalExclusionCriteriaTranslations":[]}]},"endPoint":{"primaryEndPoints":[{"id":1119076,"number":1,"endPoint":"Time to awakening within 30 days (overall safety)","isPrimary":true,"endPointTranslations":[]}],"secondaryEndPoints":[{"id":1119077,"number":1,"endPoint":"Number of participants with one or more SARs/SAEs at day 50","isPrimary":false,"endPointTranslations":[]},{"id":1119078,"number":2,"endPoint":"Any neuropsychiatric side effects until day 50 (e.g., hallucinations, anxiety, suicidality, signs of other psychological distress) after receiving psilocybin that warrants medical attention by the attending physicians using standard clinical care like application of sedatives/benzodiazepines and/or neuroleptic medication and non-pharmacological interventions","isPrimary":false,"endPointTranslations":[]},{"id":1119079,"number":3,"endPoint":"Improvement of conscious state after study drug administration, as measured by FOUR (≥2 points) and/or SECONDs (≥1 point) scores, at days 0, 1 and 7 (exploratory endpoint)","isPrimary":false,"endPointTranslations":[]},{"id":1119080,"number":4,"endPoint":"Improvement of conscious state after study drug administration, as measured by improvement across DoC categories, at days 0, 1 and 7 (exploratory endpoint)","isPrimary":false,"endPointTranslations":[]},{"id":1119081,"number":5,"endPoint":"Significantly larger median pupillary size during passive and active paradigms compared to the immediate rest periods prior and after administration of psilocybin and apomorphine, as measured by automated pupillometer (exploratory endpoint)","isPrimary":false,"endPointTranslations":[]},{"id":1119082,"number":6,"endPoint":"EEG connectivity measures (e.g., low-frequency power, electroencephalography complexity, and information exchange) and EEG artefacts (e.g., eye movements, muscle artefacts) (exploratory endpoint)","isPrimary":false,"endPointTranslations":[]},{"id":1119202,"number":7,"endPoint":"Days alive outside ICU, Cerebral Performance Category (CPC), Glasgow Outcome Scale Extended (GOS-E) and modified Rankin Scale (mRS) at day 90 (exploratory endpoint)","isPrimary":false,"endPointTranslations":[]}]},"trialDuration":{"estimatedEndDate":"2028-12-31","estimatedRecruitmentStartDate":"2024-01-01"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":386389,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":386388,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[{"id":386390,"ageRangeCategoryCode":"3","ctAgeRangeCode":"9","ageRangeCategory":"3","ctAgeRange":"9"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"3","planDescription":"N/A"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":37121,"ctNumber":"2023-503617-30-00","sponsorName":"Rigshospitalet","fullTitle":"Boosting recovery through excitation of arousal and awareness in comatose patients: The BREA2KTHROUGH trial","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":3843,"hasDocument":false,"associatedCtDocs":[]},{"id":37120,"ctNumber":"2023-503617-30-01","sponsorName":"Rigshospitalet","fullTitle":"Boosting recovery through excitation of arousal and awareness in comatose patients: The BREA2KTHROUGH trial","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":8054,"hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-27","conclusionDate":"2025-02-27","therapeuticAreas":[{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}],"medicalConditions":[{"id":147255,"medicalCondition":"Coma and other disorders of consciousness due to acute traumatic and non-traumatic brain injury","isConditionRareDisease":false}],"sponsors":[{"id":160153,"primary":true,"publicContacts":[{"id":472768,"type":"Public","functionalName":"Daniel Kondziella","functionalEmailAddress":"daniel.kondziella@regionh.dk","telephone":"+4535456368","organisation":{"id":82055,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":472769,"type":"Scientific","functionalName":"Daniel Kondziella","functionalEmailAddress":"daniel.kondziella@regionh.dk","telephone":"+4535456368","organisation":{"id":82055,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":731343,"organisationAddress":{"id":79682,"organisation":{"id":82228,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Frederiksberg Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028217","organisationLocationStatus":"Active"},"address":{"addressId":83547,"oneLine":"Nordre Fasanvej 57, 1st Floor Entrance 2","addressLine1":"Nordre Fasanvej 57","addressLine2":"1st Floor Entrance 2","addressLine3":"","addressLine4":"","city":"Frederiksberg","postcode":"2000","country":2009,"countryName":"Denmark"},"phone":"004538163816","email":"direktion.BBH-FRH@regionh.dk","isBusinessKeyValidated":true,"businessKey":"LOC-100045259"},"sponsorDuties":[{"id":1133517,"code":"1"}],"phoneNumber":"004538163816","email":"direktion.BBH-FRH@regionh.dk"}],"organisation":{"id":82055,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"addresses":[{"id":79510,"organisation":{"id":82055,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"address":{"addressId":83371,"oneLine":"Blegdamsvej 9","addressLine1":"Blegdamsvej 9","addressLine2":"","addressLine3":"","addressLine4":"","city":"Copenhagen Oe","postcode":"2100","country":2009,"countryName":"Denmark"},"isBusinessKeyValidated":true,"businessKey":"LOC-100005496"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"This is an embedded dose-finding phase 1 study (n=12 patients, i.e., 4 patients with 1mg, 4 patients with 10mg, and 4 patients with 25mg; BREA2KTHROUGH DOSEFINDER) for safety, followed by a regional collaborative, randomized trial with 1:1:1 allocation of n=384 comatose patients in the ICU (phase 2, BREA2KTRHOUGH TRIAL).","partOneTherapeuticAreas":[{"id":1225609,"therapeuticArea":{"code":"10","name":"Diseases [C] - Nervous System Diseases [C10]"}}],"productRoleGroupInfos":[{"id":435130,"comments":"Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske, oppløsning","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":585912,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10320433","productPharmForm":"INFUSJONSVÆSKE, OPPLØSNING","euMpNumber":"PRD2128245","marketingAuthNumber":"5846","prodAuthStatus":2,"prodName":"Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske, oppløsning","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"SODIUM CHLORIDE","euSubstNumber":"SUB12581MIG","authorisationCountryCode":"NO","nameOrg":"FRESENIUS KABI NORGE AS","productSubstances":[{"productPk":"10320433","substancePk":"271557","nameOrg":"FRESENIUS KABI NORGE AS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"SODIUM CHLORIDE","substanceEvCode":"SUB12581MIG","synonyms":["SODIUM CHLORID","SODIUM CHLORIDE (FOR PH ADJUSTMENT)"]}],"atcCode":"B05BB01","atcName":"ELECTROLYTES","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"3","orphanDrugEdit":false,"doseUom":"mg/g milligram(s)/gram","maxDailyDoseAmount":"10","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD2128245","devices":[],"characteristics":[],"routes":["INTRAVENOUS"],"allSubstancesChemicals":true,"productName":"Natriumklorid Fresenius Kabi 9 mg/ml infusjonsvæske, oppløsning","jsonActiveSubstanceNames":"sodium chloride","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]},{"id":435132,"comments":"PEX010 Psilocybin Capsules ( 25mg psilocybin)","miaNumber":"244/0575/18","productRoleCode":"1","productRoleName":"Test","products":[{"id":585914,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"10405999","productPharmForm":"CAPSULES","euMpNumber":"PRD10405999","prodAuthStatus":1,"prodName":"PEX010 Psilocybin Capsules ( 25mg psilocybin)","pharmForm":"CAPSULES","activeSubstanceName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","euSubstNumber":"SUB267722","nameOrg":"RIGSHOSPITALET","productSubstances":[{"productPk":"10405999","substancePk":"267731","nameOrg":"RIGSHOSPITALET","substanceOrigin":"Specified Substance Group 1","actSubstOrigin":"Specified Substance Group 1","actSubstName":"DRY EXTRACT FROM PSILOCYBE CUBENSIS (15-25:1), EXTRACTION SOLVENT: METHANOL","substanceEvCode":"SUB267722"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"25","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"25","maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD10405999","miaNumber":"244/0575/18","devices":[],"characteristics":["2","9"],"routes":["ORAL"],"allSubstancesChemicals":false,"productName":"PEX010 Psilocybin Capsules ( 25mg psilocybin)","jsonActiveSubstanceNames":"dry extract from psilocybe cubensis (15-25:1), extraction solvent: methanol","pharmaceuticalFormDisplay":"CAPSULES"}]},{"id":435131,"comments":"Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning","productRoleCode":"1","productRoleName":"Test","products":[{"id":585913,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"9569176","productPharmForm":"INFUSJONSVÆSKE, OPPLØSNING","euMpNumber":"PRD8079974","marketingAuthNumber":"12-9111","prodAuthStatus":2,"prodName":"Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"APOMORPHINE HYDROCHLORIDE HEMIHYDRATE","euSubstNumber":"SUB12924MIG","authorisationCountryCode":"NO","mrpNumber":"SE/H/1272/001","nameOrg":"EVOLAN PHARMA AB","productSubstances":[{"productPk":"9569176","substancePk":"258501","nameOrg":"EVOLAN PHARMA AB","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"APOMORPHINE HYDROCHLORIDE HEMIHYDRATE","substanceEvCode":"SUB12924MIG"}],"atcCode":"N04BC07","atcName":"APOMORPHINE","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"2","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"2","productChangedRelationMA":false,"maxTreatmentPeriod":1,"timeUnitCode":"1","evCode":"PRD8079974","devices":[],"characteristics":["2"],"routes":["SUBCUTANEOUS"],"allSubstancesChemicals":true,"productName":"Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning","jsonActiveSubstanceNames":"apomorphine hydrochloride hemihydrate","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":179080,"mscId":20192,"mscInfo":{"id":20192,"clinicalTrialId":10754,"countryOrganisationId":2009,"reportingStatusCode":"Authorised","fromDate":"2024-05-21","toDate":"2024-05-21","isProposedRms":true,"countryName":"Denmark","organisationInfo":{},"firstDecisionDate":"2024-05-28","trialStatus":"Authorised","trialPeriod":[{"id":53591,"trialStartDate":"2025-02-26","fromDate":"2025-03-27"},{"id":53592,"trialStartDate":"2025-02-26","fromDate":"2025-03-27"}],"trialRecruitmentPeriod":[{"id":71966,"recruitmentStartDate":"2025-02-26","fromDate":"2025-03-27"},{"id":71967,"recruitmentStartDate":"2025-02-26","fromDate":"2025-03-27"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":76734,"trialStartDate":"2025-02-26","fromDate":"2025-03-27"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-02-26"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":26549,"mscId":20192,"trialStatus":"Under evaluation","trialStatusDate":"2024-03-12T12:32:38.962"},{"id":35992,"mscId":20192,"trialStatus":"Authorised","trialStatusDate":"2024-05-28T07:46:20.489"}],"applicationTypeMsc":"1","mscName":"Denmark","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-21","decision":"authorized","decisionDate":"2024-05-28"},"decisionDate":"2024-05-28","recruitmentSubjectCount":384,"trialSites":[{"id":1153491,"organisationAddressInfo":{"id":80477,"organisation":{"id":83032,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"address":{"addressId":84374,"oneLine":"Nordre Ringvej 57","addressLine1":"Nordre Ringvej 57","addressLine2":"","addressLine3":"","addressLine4":"","city":"Glostrup","postcode":"2600","country":2009,"countryName":"Denmark"},"phone":"38630888","email":"margit.smitt.01@regionh.dk","isBusinessKeyValidated":true,"businessKey":"LOC-100039282"},"personInfo":{"id":1289695,"firstName":"Margit","lastName":"Smitt","telephone":"38630888","email":"margit.smitt.01@regionh.dk","title":"1"},"departmentName":"Dept. of Neuroanaestelogy, Rigshospitalet-Glostrup, Copenhagen University Hospital"},{"id":1153492,"organisationAddressInfo":{"id":80475,"organisation":{"id":83030,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Rigshospitalet","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100002431","organisationLocationStatus":"Active"},"address":{"addressId":84372,"oneLine":"Blegdamsvej 9","addressLine1":"Blegdamsvej 9","addressLine2":"","addressLine3":"","addressLine4":"","city":"Copenhagen Oe","postcode":"2100","country":2009,"countryName":"Denmark"},"phone":"+4560131100","email":"daniel.kondziella@regionh.dk","isBusinessKeyValidated":true,"businessKey":"LOC-100005496"},"personInfo":{"id":1289696,"firstName":"Daniel","lastName":"Kondziella","telephone":"+4560131100","email":"daniel.kondziella@regionh.dk","title":"1"},"departmentName":"Dept. of Neurology (sect 7076), Rigshospitalet-Blegdamsvej, Copenhagen University Hospital"},{"id":1153490,"organisationAddressInfo":{"id":80479,"organisation":{"id":83034,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Bispebjerg Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028742","organisationLocationStatus":"Active"},"address":{"addressId":84376,"oneLine":"Bispebjerg Bakke 23","addressLine1":"Bispebjerg Bakke 23","addressLine2":"","addressLine3":"","addressLine4":"","city":"Copenhagen Nv","postcode":"2400","country":2009,"countryName":"Denmark"},"phone":"+4524910542","email":"christian.sylvest.meyhoff@regionh.dk","isBusinessKeyValidated":true,"businessKey":"LOC-100045913"},"personInfo":{"id":1289694,"firstName":"Christian Sylvest","lastName":"Meyhoff","telephone":"+4524910542","email":"christian.sylvest.meyhoff@regionh.dk","title":"2"},"departmentName":"Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital, Copenhagen University Hospital"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":16563,"type":"INITIAL","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2023-12-05","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-03-11"},"partIIInfo":[{"id":101203,"mscId":20192,"mscInfo":{"id":20192,"mscName":"Denmark","countryOrganisationId":2009,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-05-27","decision":"authorized","decisionDate":"2024-05-28","reportingStatusCode":"Authorised","countryName":"Denmark","trialStatus":"Authorised","firstDecisionDate":"2024-05-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-05-28","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"IN-2","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":23025,"applicationId":16563,"mscId":20192,"mscName":"Denmark","decisionDate":"2024-05-28T07:46:20.747","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":101203,"part1Id":31934,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":96716}]},{"id":31032,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2024-07-12","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-31"},"partIIInfo":[],"decisionDate":"2024-07-31","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":31696,"applicationId":31032,"mscId":20192,"mscName":"Denmark","decisionDate":"2024-07-31T14:09:57.948","decision":"authorized","eventType":"decision","part1Id":47055,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":146902}]},{"id":42824,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2024-12-04","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-07-31"},"partIIInfo":[],"decisionDate":"2024-12-04","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":49631,"applicationId":42824,"mscId":20192,"mscName":"Denmark","decisionDate":"2024-12-04T14:34:23.234","decision":"authorized","eventType":"decision","part1Id":66195,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":207700}]},{"id":43411,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2024-12-10","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-12-18"},"partIIInfo":[],"decisionDate":"2024-12-18","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":51584,"applicationId":43411,"mscId":20192,"mscName":"Denmark","decisionDate":"2024-12-18T12:08:29.966","decision":"authorized","eventType":"decision","part1Id":67830,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":212478}]},{"id":46298,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2025-01-23","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-27"},"partIIInfo":[{"id":179080,"mscId":20192,"mscInfo":{"id":20192,"mscName":"Denmark","countryOrganisationId":2009,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-21","decision":"authorized","decisionDate":"2024-05-28","reportingStatusCode":"Authorised","countryName":"Denmark","trialStatus":"Authorised","firstDecisionDate":"2024-05-28"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-02-27","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":59748,"applicationId":46298,"mscId":20192,"mscName":"Denmark","decisionDate":"2025-02-27T13:52:35.656","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":179080,"part1Id":73388,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":229377}]},{"id":53253,"type":"SUBSTANTIAL MODIFICATION","status":"Not authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2025-04-12","partI":{},"partIIInfo":[{"id":204724,"mscId":20192,"mscInfo":{"id":20192,"mscName":"Denmark","countryOrganisationId":2009,"assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2025-06-03","decision":"authorized","decisionDate":"2024-05-28","reportingStatusCode":"Authorised","countryName":"Denmark","trialStatus":"Authorised","firstDecisionDate":"2024-05-28"},"applicationStatusCode":"Not authorised"}],"ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"SM-5","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":256189}]},{"id":86812,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2026-06-11","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-27"},"partIIInfo":[],"decisionDate":"2026-06-11","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"NSM-4","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":128081,"applicationId":86812,"mscId":20192,"mscName":"Denmark","decisionDate":"2026-06-11T09:10:45.432","decision":"authorized","eventType":"decision","part1Id":132668,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":410399}]},{"id":92113,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2023-503617-30-02","trialStatus":"Authorised","submissionDate":"2026-08-13","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-02-27"},"partIIInfo":[],"decisionDate":"2026-08-13","ctMSCsByApplication":[{"id":20192,"mscName":"Denmark","reportingStatusCode":"Authorised"}],"businessKey":"NSM-5","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":137701,"applicationId":92113,"mscId":20192,"mscName":"Denmark","decisionDate":"2026-08-13T23:17:23.724","decision":"authorized","eventType":"decision","part1Id":140578,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","productRoleGroupId":435132}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Denmark","mscId":20192,"firstDecisionDate":"2024-05-28T07:46:20.747","lastDecisionDate":"2025-02-27T13:52:35.656","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":20192,"mscName":"Denmark","events":[{"notificationType":"START_OF_TRIAL","date":"2025-02-26"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-02-26"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"informedconsent_patientrecruitmentprocedure","uuid":"0b537687-1e77-4dcc-8f7c-b07011ce3b31","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":179080,"manualVersion":"1.1","systemVersion":"1"},{"title":"Dine rettigheder som forsgsperson i forsg med medicin","uuid":"7f10a3bd-bbd4-4ad3-94ae-e22a564ae879","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":179080,"manualVersion":"1","systemVersion":"1"},{"title":"Samtykkeerklring Patient","uuid":"6a3c0ac1-579b-41af-b50e-49e607eef4fb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.1","systemVersion":"1"},{"title":"Stedfortrdende Samtykke","uuid":"5f76a0c8-7475-41a0-b801-9450a99e99cd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.1","systemVersion":"1"},{"title":"Deltagerinformation Patient_track changes","uuid":"713691a6-8ce9-47f6-a520-4f67dc5fc934","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.2","systemVersion":"1"},{"title":"Deltagerinformation Paarrende","uuid":"2958c766-9e76-41c3-8ec3-6130048913ea","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.2","systemVersion":"1"},{"title":"Deltagerinformation Paarrende_track changes","uuid":"25b45cdd-8c19-4ca5-94c4-5848c299a752","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.2","systemVersion":"1"},{"title":"Deltagerinformation Patient","uuid":"21a126a2-69cc-4e5a-b39b-fd7becd8ecad","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"DOCX","associatedEntityId":179080,"manualVersion":"1.2","systemVersion":"1"},{"title":"Protocol BREA2KTHROUGH","uuid":"6e7713a2-be2b-404f-8bd3-b89543819449","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":140578,"manualVersion":"1.4.2","systemVersion":"1"},{"title":"Protocol BREA2KTHROUGH_track changes","uuid":"7528a349-3ba6-4b34-a30a-4110ee8b63fd","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":140578,"manualVersion":"1.4.2","systemVersion":"1"},{"title":"BREA2KTHROUGH DOSEFINDER_one pager","uuid":"9d0bcfb2-e82a-4ea9-9073-43350813ff9f","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":140578,"manualVersion":"1","systemVersion":"1"},{"title":"Protocol synopsis Danish","uuid":"52b19b95-1127-4b29-bd18-e13ebdc48ab7","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":140578,"manualVersion":"1","systemVersion":"1"},{"title":"Placeholder document","uuid":"ee8edd23-5ca8-4fee-9dfa-f564695b6585","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":435132,"manualVersion":"1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}